Regentis Biomaterials to Present at the 2026 ThinkEquity Conference on October 15 in New York City

Regentis Biomaterials (RGNT) will present at the 2026 ThinkEquity Conference in New York City on October 15, 2026.

Rhea-AI Summary

Regentis Biomaterials (RGNT) will present at the 2026 ThinkEquity Conference in New York City on October 15, 2026. CEO and Executive Chairman Ehud Geller will speak from 10:00–10:30 at the Mandarin Oriental Hotel. CFO Ori Gon will join him, and both executives will be available for one-on-one investor meetings.

The presentation will cover GelrinC technology, recent clinical developments, the ongoing U.S. FDA pivotal Phase III trial and preparations for European commercialization. GelrinC has CE Mark approval in the European Union, and its pivotal FDA study has completed over 50% enrollment.

Argus 15 min delay 2 alerts

+6.63% vs previous close $1.71 last price 0.9x rel. volume Open Argus

Details

Market move: RGNT +6.63% vs previous close. 2026 conference presentation

$1.62 – $1.74 Day Range

$11.98M Market Cap

On Oct 9, the day this news came out, the latest delayed price for RGNT is 6.63% above the previous close. Our momentum scanner has recorded 2 alerts for this stock so far that day. The latest delayed price is $1.71.

Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.

Key Terms

phase iii trial, ce mark approval, resorption

3 terms

phase iii trial medical

"progress in its ongoing U.S. FDA pivotal Phase III trial"

A phase III trial is a large, late-stage clinical study that tests whether a new drug or medical treatment works and is safe in a broad group of patients; think of it as the final road test before regulators decide if a product can be sold widely. Investors watch these trials closely because positive results often trigger regulatory approval and major increases in a company’s value, while failures can sharply reduce prospects and share price.

ce mark approval regulatory

"where GelrinC has received CE Mark approval"

CE mark approval is a declaration that a product meets European safety, health and performance requirements and may be placed on the market in the European Economic Area; for regulated items such as medical devices this follows required testing or a conformity assessment. Think of it as a passport or safety sticker that opens access to European customers; for investors it reduces regulatory roadblocks and can materially expand addressable market and revenue potential, though it is not a guarantee of commercial success.

resorption medical

"having synchronized erosion and resorption"

Resorption is the biological process by which the body breaks down and removes tissue or material and transfers its components into the bloodstream or surrounding tissues. It commonly describes bone or tooth material being dissolved by specialized cells (for example, osteoclasts in bone), or the gradual disappearance of tissue or a structure as it is absorbed, and can occur as a normal part of growth and healing or as a pathological process. The term refers to the physical removal and reutilization of tissue components, not to external degradation or mechanical removal.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

HERZLIYA, IL / ACCESS Newswire / October 9, 2026 / Regentis Biomaterials Ltd. ("Regentis" or the "Company") (NYSE American:RGNT), a regenerative medicine company focused on innovative tissue repair solutions, today announced that Ehud Geller, Chief Executive Officer and Executive Chairman, will present at the 2026 ThinkEquity Conference on Thursday, October 15, 2026. Dr. Geller will be joined by Ori Gon, Chief Financial Officer, and both will be available for one-on-one meetings with investors.

Dr. Geller will provide an overview of Regentis' GelrinC® technology, recent clinical developments, progress in its ongoing U.S. FDA pivotal Phase III trial, and preparations for commercialization in Europe, where GelrinC has received CE Mark approval.

Conference Details

• Event: 2026 ThinkEquity Conference
• Date: Thursday, October 15, 2026
• Location: Lotus Suite East, Mandarin Oriental Hotel, 80 Columbus Circle, New York, NY
• Presenter: Ehud Geller, PhD, CEO and Executive Chairman
• Presentation Time: 10:00-10:30

To request a one-on-one meeting with management, please contact your Think Equity representative. For additional information about the conference, please visit the ThinkEquity Conference website.

About GelrinC^®

Regentis' lead product, GelrinC^®, is a cell-free, off-the-shelf hydrogel implant having synchronized erosion and resorption for the treatment of painful and debilitating injuries to focal articular knee cartilage. As an innovative regenerative medical product, GelrinC^® offers an unprecedented solution that gives surgeons and payers an off-the-shelf, ready to use, simple to perform, reliable, and cost-effective procedure that provides patients with a single, 10-minute procedure, faster recovery, sustained pain relief, and functional improvement for more than 5 years, based on clinical study results to date. No effective off-the-shelf, ready to use treatment for focal knee cartilage defects is currently available on the market. GelrinC^® has CE Mark approval in the European Union and is now being evaluated in a pivotal U.S. Food and Drug Administration (FDA) study, which has completed over 50% enrollment.

About Regentis Biomaterials

Regentis Biomaterials Ltd is a regenerative medicine company dedicated to developing innovative tissue repair solutions that restore health and enhance quality of life. With an initial focus on orthopedic treatments, Regentis' Gelrin platform technology, based on synchronized, degradable hydrogel implants, regenerates damaged or diseased tissue including inflamed cartilage and bone. Regentis' lead product GelrinC^®, is a cell-free, off-the-shelf hydrogel that is eroded and resorbed in the knee, allowing the surrounding cells to regenerate the cartilage in a controlled and synchronous process. GelrinC^® aims to address a market of approximately 470,000 cases for cartilage knee repair annually in the U.S. where no off-the-shelf treatment is available.

Forward Looking Statements

This press release contains "forward-looking statements" that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as "anticipate," "believe," "contemplate," "could," "estimate," "expect," "intend," "seek," "may," "might," "plan," "potential," "predict," "project," "target," "aim," "should," "will" "would," or the negative of these words or other similar expressions, although not all forward-looking statements contain these words, and include beliefs regarding Regentis' plans to commence European surgeon activities and the timing thereof. Forward-looking statements are based on Regentis' current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. Factors that may affect future results and may cause these forward-looking statements to be inaccurate include, without limitation: the ability of our clinical trials to demonstrate safety and efficacy of GelrinC or any future product candidate, and other positive results; the timing and focus of our preclinical studies and clinical trials, and the reporting of data from those studies and trials; the size of the market opportunity for of GelrinC or any future product candidate, including our estimates of the number of patients who suffer from the diseases we are targeting; our ability to accurately identify demand for product candidates; the success of competing therapies that are or may become available; the beneficial characteristics, safety, efficacy and therapeutic effects of our product candidates; our ability to obtain FDA approval for of GelrinC or any future product candidate and obtain and maintain regulatory approval; our ability to obtain market acceptance of GelrinC or any future product candidate from the medical community and third-party payors; our plans relating to the further development of GelrinC or any future product candidate, including additional disease states or indications we may pursue; existing regulations and regulatory developments in the United States and other jurisdictions; our plans and ability to obtain or protect intellectual property rights, including extensions of patent terms where available and our ability to avoid infringing the intellectual property rights of others; the need to hire additional personnel and our ability to attract and retain such personnel; our estimates regarding expenses, future revenue, capital requirements and needs for additional financing; our dependence on third parties; our financial performance and our ability to repay our loans and debts; and our ability to negotiate favorable terms in any collaboration, licensing or other arrangements into which we may enter and perform our obligations under such collaborations. For a more detailed description of the risks and uncertainties affecting Regentis, reference is made to the Company's reports filed from time to time with the Securities and Exchange Commission ("SEC"), including, but not limited to, the risks detailed in the section titled "Risk Factors" in our Annual Report on Form 20-F filed with the SEC on February 24, 2026 and other public reports filed with the SEC. Forward-looking statements contained in this announcement are made as of this date, and Regentis undertakes no duty to update such information except as required under applicable law.

Contact:
Ori@regentis.co.il

SOURCE: Regentis Biomaterials Ltd

View the original press release on ACCESS Newswire